WT1 Promotes Cell Proliferation in Non-Small Cell Lung Cancer Cell Lines through Up-Regulating Cyclin D1 and p-pRb In Vitro and In Vivo

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Xu, Caihua ^a   Wu, Chen ^b   Xia, Yang ^b   Zhong, Zhaopeng ^b   Liu, Xiang ^b   Xu, Jing ^b   Cui, Fei ^c   Chen, Bin ^d   Røe, Oluf Dimitri ^e   Li, Aihong ^f   Chen, Yijiang ^b  

^a THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^c GUANGZHOU MEDICAL UNIVERSITY   (China)

^d WUXI NO 2 PEOPLE S HOSPITAL   (China)

^e NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^f UMEÅ UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; MESSENGER RNA; RETINOBLASTOMA PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; GENE EXPRESSION; GENE FUNCTION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT; UPREGULATION;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN D1; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MICE; PHOSPHOPROTEINS; RETINOBLASTOMA PROTEIN; RNA, MESSENGER; STAT3 TRANSCRIPTION FACTOR; TRANSCRIPTIONAL ACTIVATION; UP-REGULATION; WT1 PROTEINS;

EID: 84880992608     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0068837     Document Type: Article

References (37)

1. Siegel R, Naishadham D, Jemal A, (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10-29.
2. van Meerbeeck JP, Fennell DA, De Ruysscher DK, (2011) Small-cell lung cancer. Lancet 378: 1741-1755.
3. Goldstraw P, Ball D, Jett JR, Le Chevalier T, Lim E, et al. (2011) Non-small-cell lung cancer. Lancet 378: 1727-1740.
4. Yang L, Parkin DM, Ferlay J, Li L, Chen Y, (2005) Estimates of cancer incidence in China for 2000 and projections for 2005. Cancer Epidemiol Biomarkers Prev 14: 243-250.
5. Herbst RS, Heymach JV, Lippman SM, (2008) Lung cancer. N Engl J Med 359: 1367-1380.
6. Brundage MD, Davies D, Mackillop WJ, (2002) Prognostic factors in non-small cell lung cancer: a decade of progress. Chest 122: 1037-1057.
7. Gallardo E, Navarro A, Vinolas N, Marrades RM, Diaz T, et al. (2009) miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. Carcinogenesis 30: 1903-1909.
8. Call KM, Glaser T, Ito CY, Buckler AJ, Pelletier J, et al. (1990) Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 60: 509-520.
9. Gessler M, Poustka A, Cavenee W, Neve RL, Orkin SH, et al. (1990) Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping. Nature 343: 774-778.
10. Keilholz U, Menssen HD, Gaiger A, Menke A, Oji Y, et al. (2005) Wilms' tumour gene 1 (WT1) in human neoplasia. Leukemia 19: 1318-1323.
11. Oji Y, Miyoshi S, Maeda H, Hayashi S, Tamaki H, et al. (2002) Overexpression of the Wilms' tumor gene WT1 in de novo lung cancers. Int J Cancer 100: 297-303.
12. Thomas A, Hassan R, (2012) Immunotherapies for non-small-cell lung cancer and mesothelioma. Lancet Oncol 13: e301-310.
13. Bowman T, Garcia R, Turkson J, Jove R, (2000) STATs in oncogenesis. Oncogene 19: 2474-2488.
14. Bromberg J, (2002) Stat proteins and oncogenesis. J Clin Invest 109: 1139-1142.
15. Darnell JE, (2005) Validating Stat3 in cancer therapy. Nat Med 11: 595-596.
16. Sinibaldi D, Wharton W, Turkson J, Bowman T, Pledger WJ, et al. (2000) Induction of p21WAF1/CIP1 and cyclin D1 expression by the Src oncoprotein in mouse fibroblasts: role of activated STAT3 signaling. Oncogene 19: 5419-5427.
17. Catlett-Falcone R, Dalton WS, Jove R, (1999) STAT proteins as novel targets for cancer therapy. Signal transducer an activator of transcription. Curr Opin Oncol 11: 490-496.
18. Rong Y, Cheng L, Ning H, Zou J, Zhang Y, et al. (2006) Wilms' tumor 1 and signal transducers and activators of transcription 3 synergistically promote cell proliferation: a possible mechanism in sporadic Wilms' tumor. Cancer Res 66: 8049-8057.
19. Loeb DM, Sukumar S, (2002) The role of WT1 in oncogenesis: tumor suppressor or oncogene? Int J Hematol 76: 117-126.
20. Hayashi S, Oji Y, Kanai Y, Teramoto T, Kitaichi M, et al. (2012) Low Wilms' tumor gene expression in tumor tissues predicts poor prognosis in patients with non-small-cell lung cancer. Cancer Invest 30: 165-171.
21. Vicent S, Chen R, Sayles LC, Lin C, Walker RG, et al. (2010) Wilms tumor 1 (WT1) regulates KRAS-driven oncogenesis and senescence in mouse and human models. J Clin Invest 120: 3940-3952.
22. Levy DE, Darnell JE Jr, (2002) Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 3: 651-662.
23. Fernandes A, Hamburger AW, Gerwin BI, (1999) ErbB-2 kinase is required for constitutive stat 3 activation in malignant human lung epithelial cells. Int J Cancer 83: 564-570.
24. Lundberg AS, Weinberg RA, (1998) Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol Cell Biol 18: 753-761.
25. Duronio RJ, O'Farrell PH, Xie JE, Brook A, Dyson N, (1995) The transcription factor E2F is required for S phase during Drosophila embryogenesis. Genes Dev 9: 1445-1455.
26. Cobrinik D, (2005) Pocket proteins and cell cycle control. Oncogene 24: 2796-2809.
27. Connell-Crowley L, Harper JW, Goodrich DW, (1997) Cyclin D1/Cdk4 regulates retinoblastoma protein-mediated cell cycle arrest by site-specific phosphorylation. Mol Biol Cell 8: 287-301.
28. Hanahan D, Weinberg RA, (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674.
29. Martinez-Estrada OM, Lettice LA, Essafi A, Guadix JA, Slight J, et al. (2010) Wt1 is required for cardiovascular progenitor cell formation through transcriptional control of Snail and E-cadherin. Nat Genet 42: 89-93.
30. Kim HS, Kim MS, Hancock AL, Harper JC, Park JY, et al. (2007) Identification of novel Wilms' tumor suppressor gene target genes implicated in kidney development. J Biol Chem 282: 16278-16287.
31. Onder TT, Gupta PB, Mani SA, Yang J, Lander ES, et al. (2008) Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res 68: 3645-3654.
32. Tuna M, Chavez-Reyes A, Tari AM, (2005) HER2/neu increases the expression of Wilms' Tumor 1 (WT1) protein to stimulate S-phase proliferation and inhibit apoptosis in breast cancer cells. Oncogene 24: 1648-1652.
33. Mayo MW, Wang CY, Drouin SS, Madrid LV, Marshall AF, et al. (1999) WT1 modulates apoptosis by transcriptionally upregulating the bcl-2 proto-oncogene. EMBO J 18: 3990-4003.
34. Cheema SK, Mishra SK, Rangnekar VM, Tari AM, Kumar R, et al. (2003) Par-4 transcriptionally regulates Bcl-2 through a WT1-binding site on the bcl-2 promoter. J Biol Chem 278: 19995-20005.
35. McKay LM, Carpenter B, Roberts SG, (1999) Regulation of the Wilms' tumour suppressor protein transcriptional activation domain. Oncogene 18: 6546-6554.
36. Carpenter B, Hill KJ, Charalambous M, Wagner KJ, Lahiri D, et al. (2004) BASP1 is a transcriptional cosuppressor for the Wilms' tumor suppressor protein WT1. Mol Cell Biol 24: 537-549.
37. Rico M, Mukherjee A, Konieczkowski M, Bruggeman LA, Miller RT, et al. (2005) WT1-interacting protein and ZO-1 translocate into podocyte nuclei after puromycin aminonucleoside treatment. Am J Physiol Renal Physiol 289: F431-441.